First drug approved in 2021

Poxel is developing a pipeline of several mid-to-late-stage drug candidates targeting the mitochondrial dysfunction. Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and was launched in September 2021. Imeglimin has also successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases with the objective to launch Phase 2a proof-of-concept studies in ALD early 2022.

VIEW OUR CANDIDATES

Latest News

Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic…

Read this Press Release: Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021

TWYMEEG® (Imeglimin hydrochloride) launched in Japan on September 16 for the treatment of type 2 diabetes Milestone payment for TWYMEEG’s approval in Japan of JPY 1.75 billion (approximately EUR 13.2 million,…

Read this Press Release: Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021

Poxel Announces its Participation at Investor Conferences in October 2021

Lyon, France, September 30, 2021 - POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic…

Read this Press Release: Poxel Announces its Participation at Investor Conferences in October 2021
Click here to show the previous slide Click here to show the next slide

Upcoming Events

NASH Summit

Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

Targeting Mitochondrial Dysfunction

Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and will be marketed by our strategic partner, Sumitomo Dainippon Pharma, in 2021. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership